Clinical trial
CCI-779 in Treating Patients With Malignant Glioma
NCT00022724 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other · Completed
Key facts
| NCT number | NCT00022724 |
|---|---|
| Title | CCI-779 in Treating Patients With Malignant Glioma |
| Official title | Phase I/II Trial Of CCI-779 In Patients With Malignant Glioma |
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | temsirolimus |
| Enrollment | 49 |
| Start date | Aug 27, 2001 |
| Primary completion | May 4, 2006 |
| Completion | Dec 15, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 26, 2018 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: